Raltitrexed (Tomudex(TM)) in combination with platinum-based agents and/or anthracyclines: Preliminary results of phase I clinical trials

European Journal of Cancer

Volumn 35, Issue SUPPL. 1, 1999, Pages

  Armand, J P ^a   Seymour, L ^c   Evans, T R J ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c NONE

Author keywords

Anthracyclines; Colorectal cancer; Doxorubicin; Mesothelioma; Oxaliplatin; Raltitrexed

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; OXALIPLATIN; RALTITREXED; ANTINEOPLASTIC AGENT; ECT PROTOCOL; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; ESOPHAGUS CARCINOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CARCINOMA; ARTICLE; COLORECTAL TUMOR; DIGESTIVE SYSTEM TUMOR; DRUG ADMINISTRATION; FEMALE; MESOTHELIOMA; MULTICENTER STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; MESOTHELIOMA; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; THIOPHENES; TREATMENT OUTCOME;

EID: 0033103561     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00043-X     Document Type: Conference Paper

References (28)

1. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998, 77(Suppl. 2), 15-21.
2. Zalcberg JR, Cunningham D, Van Cutsem E, et al. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 1996, 14, 716-721.
3. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998, 25(Suppl. 5), 4-12.
4. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998, 9, 1053-1071.
5. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res 1993, 53, 5970-5976.
6. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II): New experimental data. Biomed Pharmacother 1989, 43, 251-260.
7. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7, 95-98.
8. Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer. Semin Oncol 1998, 25(Suppl. 5), 23-31.
9. Ducreux M, Louvet C, Bekradda M, Cvitkovic E. Oxaliplatin for the treatment of advanced colorectal cancer: Future directions. Semin Oncol 1998, 25(Suppl. 5), 47-53.
10. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997, 33, 214-219.
11. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996, 14, 2950-2958.
12. Hill ME, Cunningham D. Medical management of advanced gastric cancer. Cancer Treat Rev 1998, 24, 113-118.
13. Schipper DL, Wagener DJT. Chemotherapy of gastric cancer. Anticancer Drugs 1996, 7, 137-149.
14. Glimelius B, Huffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994, 5, 189-190.
15. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993, 72, 37-41.
16. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71, 587-591.
17. Bamias A, Hill ME, Cunningham D, et al. Epirubicin, cisplatin and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma. Response, toxicity, quality of life, and survival. Cancer 1996, 77, 1978-1985.
18. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994, 5, 609-616.
19. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997, 15, 261-267.
20. Ducreux M, Fizazi K, Daniel C, et al. Updated results of a phase I trial of Tomudex (T) in combination with oxaliplatin (L-OHP) in advanced solid tumors: A promising and active combination. Ann Oncol 1998, 9(Suppl. 4), 125 (abstract 602O).
21. Eatock MM, Anthony DA, Wilson P, et al. Preliminary results of a dose-finding study of 'Tomudex' with cisplatin and epirubicin as first-line therapy for metastatic or unresectable gastric and oesophageal adenocarcinoma. Ann Oncol 1998, 9(Suppl. 4), 49 (abstract 235P).
22. Bjarnason G, Charpentier D, Winquist E, Wong R, Matthews S, Seymour L. 'Tomudex' (raltitrexed) plus doxorubicin in patients with advanced gastric cancer: Interim results of a phase I dose escalation study. Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 18-19 June 1998.
23. Esaki T, Nakano S, Masumoto N, Fujishima H, Niho Y. Schedule-dependent reversion of acquired cisplatin resistance by 5- Fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 1996, 65, 479-484.
24. Norris B, Pritchard K, James K, et al. A phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) versus doxorubicin alone in metastatic/recurrent breast cancer (MBC): A National Cancer Institute of Canada (NCIC CTG) study. Procasco 1996, 15, 98 (abstract 59).
25. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998, 113(Suppl. 1), 66S-73S.
26. Kaiser LR. New therapies in the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997, 9, 383-390.
27. Manegold C, Buchholz E, Kloeppel R, Kreisel C, Smith M. Phase I dose-escalating study of 'Tomudex' ('T') and cisplatin (C) in metastatic non-small cell lung cancer (NSCLC): Preliminary results. Ann Oncol 1998, 9(Suppl. 4), 101 (abstract 487).
28. ® (raltitrexed) and cisplatin in patients with locally advanced or metastatic head and neck cancer. Ann Oncol 1998, 9(Suppl. 4), 78 (abstract 373P).